TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01755299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular 5-hour Energy
Description: Amount equivalent to the package commercially packaged and sold (1.93 fl. oz.)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decaf 5-hour Energy
Description: Commercially available 5-Hour Energy Decaf product in the amount that is packaged (1.93 fl. oz.)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compounded concentrated caffeine liquid
Description: Concentrated caffeine liquid has been used to compound a 135 mg/2 ounce caffeine product, which contains the same amount of caffeine as a regular 5-hour Energy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored bottled water
Description: Bottled water will be flavored and colored to serve as a placebo product for this trial.
Study: NCT02689960

Intervention type: DRUG
Group type: OTHER
Intervention: 100mg prednisone suppository
Description: vaginal administration of 100mg prednisone suppository (Rectodelt)

Intervention type: DRUG
Group type: OTHER
Intervention: 100mg prednisone suppository
Description: vaginal administration of 100mg prednisone suppository (Rectodelt)
Study: NCT04701996

Intervention type: BIOLOGICAL
Intervention: serological surveillance
Description: serological surveillance, detection of antibodies (Total Ig and IgM) developed against SARS-CoV-2 in a population living in a rural area (Kimpese, DRC)
Study: NCT00063622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 30 mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: 800 IU daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Daily
Study: NCT04465422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational therapy based on the MOHO theory
Description: We selected two acute wards in the Songde hospital as the intervention group and the control group. At the same time, the demographic data of the participants were collected, including gender, age, age of onset, marital status, education level, work experience, etc., and the clinical records, including assessment of mental symptoms and medication records, etc. Continuity or categorical information on Occupational performance, personal and social performance, instrumental activities daily living, and clinical performance.~OPHI-II, CGIS, PSP, LIADL, COPM, COTES were tested before and after in the intervention group and the control group to explain the intervention effect of the MOHO theory-based treatment model.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy
Description: The original Occupational therapy. OPHI-II, CGIS, PSP, LIADL, COPM, COTES were tested before and after in the intervention group and the control group to explain the intervention effect of the MOHO theory-based treatment model.
Study: NCT00630292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography (MRA) of the Breast
Description: Magnetic Resonance Angiography (MRA) of the breast will be performed before or after pre-treatment magnetic resonance imaging (MRI) and then once again before or after the post-treatment MRI.
Study: NCT02382939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: Administered subcutaneously (s.c., under the skin) with an investigational pen once weekly for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: Administered subcutaneously (s.c., under the skin) with a prefilled pen (Norditropin® FlexPro®) daily for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
Study: NCT00998153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction through Family Therapy
Description: Component based intervention based on existing empirically supported treatments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk Reduction through Family Therapy
Description: Component based intervention based on existing empirically supported treatments
Study: NCT02784639

Intervention type: OTHER
Group type: OTHER
Intervention: Tumor tissue analysis of circulating cell free DNA
Study: NCT02885467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with Saphenous nerve burial

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard total knee arthroplasty
Study: NCT03432806

Intervention type: OTHER
Intervention: blood draws
Description: Patients will have 10 mL of peripheral venous blood drawn immediately prior to surgery, in the post anesthesia care unit (PACU), and at the first postoperative clinic visit for a total of 30 mL.
Study: NCT01582451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Study: NCT02484521

Intervention type: DEVICE
Group type: OTHER
Intervention: PPI monitoring device protocol
Description: The investigators would use a monitoring device that would assess startle reflex reaction measured by blinking or the eye. Monitoring would be done with electrodes of EMG device that would be located on orbicularis oculi muscle and will monitor response.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PPI monitoring device protocol
Description: The investigators would use a monitoring device that would assess startle reflex reaction measured by blinking or the eye. Monitoring would be done with electrodes of EMG device that would be located on orbicularis oculi muscle and will monitor response.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Group of patients diagnosed with schizophrenia would be interviewed using well validated questionnaires.~Questionnaires what would be used are:~1. GAF- Global assessment of functioning~2. PANSS- Positive and negative syndrome scale~3. SANS- Scale for the Assessment of Negative Symptoms~4. The Calgary Depression Scale for schizophrenia~5. Demographic Questionnaire~6. Hamilton Anxiety scale
Study: NCT02229838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBB 1464 MS tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBB 1464 MS tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBB 1464 MS solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIBB 1464 MS placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard dinner
Study: NCT00474019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: IV qd for 4 days
Study: NCT01227174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Procedural sedation will be achieved using propofol
Study: NCT04306484

Intervention type: DIAGNOSTIC_TEST
Intervention: FDOPA-TEP
Description: FDOPA-TEP performed as part of the normal management of a suspected brain tumour
Study: NCT03479827

Intervention type: DEVICE
Intervention: Monofocal Contact Lens
Description: A monofocal contact lens will be used for this measurement.

Intervention type: DEVICE
Intervention: Bifocal Contact Lens
Description: A bifocal contact lens will be used for this measurement.
Study: NCT06342882

Intervention type: DIAGNOSTIC_TEST
Intervention: dysphagia assessment
Description: Twenty-one patients underwent the Modified Barium Swallowing Study and Swallowing Ability and Function Evaluation (SAFE) assessments. The Penetration Aspiration Scale (PAS) and SAFE physical examination, oral phase and pharyngeal phase domains was used to determine the dysphagia severity.

Intervention type: DIAGNOSTIC_TEST
Intervention: dysphagia assessment
Description: Twenty-one patients underwent the Modified Barium Swallowing Study and Swallowing Ability and Function Evaluation (SAFE) assessments. The Penetration Aspiration Scale (PAS) and SAFE physical examination, oral phase and pharyngeal phase domains was used to determine the dysphagia severity.

Intervention type: DIAGNOSTIC_TEST
Intervention: functional independence level
Description: Functional independence was evaluated by the Functional Independence Measurement (FIM) motor and cognitive domains.

Intervention type: DIAGNOSTIC_TEST
Intervention: functional independence level
Description: Functional independence was evaluated by the Functional Independence Measurement (FIM) motor and cognitive domains.
Study: NCT03211052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-700 and LHRH agonist
Description: TAK-700 for 6 months 300mg BD with Leuprorelin Acetate Injections prior to planned prostatectomy
Study: NCT02668068

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: large volume whole-lung lavage (WLL)
Description: Generally 1000 \~ 2000ml each time, 14 \~ 10 times totally, each side of the lung to 20 \~ 15 liters, until the lavage fluid from the black into a colorless clear clarification

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: large volume whole-lung lavage (WLL)
Description: Generally 1000 \~ 2000ml each time, 14 \~ 10 times totally, each side of the lung to 20 \~ 15 liters, until the lavage fluid from the black into a colorless clear clarification

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: clinical grade umbilical cord mesenchymal stem cells
Description: 10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after whole-lung lavage
Study: NCT03443297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast milk
Description: Feeding with breast milk will be started in early feeding group from 24 to 48 hours of age or in late feeding group, from 48 to 72 hours of age. Initially 4 hourly feeding will be started with 0.5ml and 1 ml expressed breast milk in babies with birth weight \<1200 grams and \>1200 grams respectively. gradually volume of milk should be increased
Study: NCT01572792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
Description: Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose, twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
Description: Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose, twice per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclidinium bromide
Description: Inhaled Aclidinium bromide 400 μg, twice per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Inhaled Formoterol Fumarate 12 μg, twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled dose-matched placebo, twice per day
Study: NCT02556788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5789 (trifarotene) 50µg/g Cream
Description: CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Placebo cream applied once daily during 12 weeks.
Study: NCT02101294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interossei Lumbricals Neuro Interface
Description: Finger Relief's keyboard home row layout \[actual home row placement order: asdeihotlrn\], plus substitutions on the upper row \[qwfgjyuk;p\] and bottom row \[zxcvb'm,.\] moves or shifts finger and thumb movement from the elbow muscles to the finger muscles. The movement of finger bending toward the palm is shifted to the interosseous and lumbrical muscles of the hand and fingers from the full flexion and extension muscle control to reduce contraction and expansion of tendons and the movement in the carpal canal adjacent to the median nerve and reduces pressure on the median nerve. Pressure on the median nerve compromises the nerve leading to symptoms of the carpal tunnel syndrome of pain, tingling, and numbness.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard QWERTY keyboard
Description: Report of onset and severity symptoms of carpal tunnel syndrome when typing with QWERTY keyboard and the Finger Relief device.
Study: NCT03979417

Intervention type: OTHER
Intervention: Blood draw and liver resection
Description: The samples are transferred to the research unit for immunological studies.

Intervention type: OTHER
Intervention: Blood draw and liver resection
Description: The samples are transferred to the research unit for immunological studies.

Intervention type: OTHER
Intervention: Blood draw and liver resection
Description: The samples are transferred to the research unit for immunological studies.
Study: NCT01979900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccae
Description: One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
Study: NCT03211052

Intervention type: PROCEDURE
Group type: OTHER
Intervention: prostatectomy
Description: SURGICAL REMOVAL OF THE PROSTATE
Study: NCT01979900

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well，once every 2 weeks, 6 times totally.
Study: NCT04684316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic survey with selective consultations
Description: Participants complete an online questionnaire, after which the 20% employees that mostly need contact with the occupational physician (based on their survey score) are invited to a consultation with the occupational physician.
Study: NCT01682031

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenomethionine
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study: NCT03718780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simultaneous determination of PaCO2 and PtCO2
Description: Patients in intensive care, equipped, for their routine clinical management, with an arterial catheter blood line, will have a simultaneous determination of PaCO2 and PtCO2:~* 1) at rest; 2 arterial CO2/PtCO2 determinations will be carried out, 10 minutes apart~* 2) During the muscular exercise part of their routine rehabilitation program (whatever it might be, limbs active mobilization, walking, etc...) : several arterial /PtCO2 samples will be collected during the first minutes of their muscular routine: 30 sec, 1 minute, 1 ½ minute, 2, 2 ½ , 3, 4, 5 minutes, 10 minutes (end of exercise). This will generate several couples of blood/transcutaneous CO2 determinations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperventilation test
Description: Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest (0), then 30 sec post beginning of hyperventilation (breathing with accelerated frequency e.g. 30/min), 1 minute, 1 ½ minute 2, 2 ½ , 3, , 4, 5 minutes; recovery of this hyperventilation will be followed, for 5 minutes, with the PtCO2, during 3 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test
Description: an exercise test, according to the routine protocol used in the clinic: initial phase of 3 minutes gentle pedaling (10 to 50 watts, according to subject capabilities), then stepwise increase in the workload, by increments of 20-40 watts every minute, until maximum tolerated workload (VO2max). Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest -10 minutes, 0, then 30 sec post beginning of exercise, 1 minute, 1 ½ minute 2, 2 ½, 3 minutes, then 3 ½ minutes, then at mid-point of every step increase in workload, until maximum tolerated workload. Recovery will be followed with the PtCO2, for 5 minutes
Study: NCT01682031

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study: NCT03718780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test
Description: an exercise test, according to the routine protocol used in the clinic: initial phase of 3 minutes gentle pedaling (10 to 50 watts, according to subject capabilities), then stepwise increase in the workload, by increments of 20-40 watts every minute, until maximum tolerated workload (VO2max). Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest -10 minutes, 0, then 30 sec post beginning of exercise, 1 minute, 1 ½ minute 2, 2 ½, 3 minutes, then 3 ½ minutes, then at mid-point of every step increase in workload, until maximum tolerated workload. Recovery will be followed with the PtCO2, for 5 minutes
Study: NCT01682031

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03001102

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 4% Chlorhexidine gluconate
Description: Cationic biguanide - antimicrobial action rubbing in the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10% PVPI degermante
Description: Polymer soluble in water of iodine with polyvinylpyrrolidone (PVP) - antimicrobial action rubbing in the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soap without antiseptic
Description: Liquid soap with glycerin, neutral pH. Skin cleansing
Study: NCT02875457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib;etoposide and cisplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo;etoposide and cisplatin
Study: NCT02598115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Pharmaceutical Care
Description: The pharmacist performs collaborative pharmaceutical care in the ward: reconciliation of drug treatments and revision of drug prescriptions indicated on the admission drug prescription. He/she emits pharmaceutical interventions recorded on the standardized support provided by the French Society of Clinical Pharmacy. The pharmaceutical interventions are discussed during a collaborative interview.
Study: NCT04278313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP - Platelet Rich Plasma
Description: Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube to leave 2.5 ml of Platelet Rich Plasma in the tube. The tube is inverted several times to suspend the platelet pellet. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PPP - Platelet Poor Plasma
Description: Using a sterile vacutainer technique two 8 ml samples of whole blood is drawn into two Regen Lab A-PRP vacutainers with gel separator and citrate. Invert the tube to mix with citrate. The whole blood undergoes two centrifugations, once for 3 minutes and again for 5 minutes. Using a 20-gauge 6-inch spinal needle 2 ml of Platelet POOR Plasma will be drawn off the supernatant from each tube. The prepared plasma will be transported to the procedure room. The prepared plasma labeled with the participants name and randomization code will be transported to the procedure room.
Study: NCT02508389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose GC4419: 30mg/day
Description: Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose GC4419: 90mg/day
Description: High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks
Study: NCT02508389

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks
Study: NCT03718780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test
Description: an exercise test, according to the routine protocol used in the clinic: initial phase of 3 minutes gentle pedaling (10 to 50 watts, according to subject capabilities), then stepwise increase in the workload, by increments of 20-40 watts every minute, until maximum tolerated workload (VO2max). Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest -10 minutes, 0, then 30 sec post beginning of exercise, 1 minute, 1 ½ minute 2, 2 ½, 3 minutes, then 3 ½ minutes, then at mid-point of every step increase in workload, until maximum tolerated workload. Recovery will be followed with the PtCO2, for 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test
Description: an exercise test, according to the routine protocol used in the clinic: initial phase of 3 minutes gentle pedaling (10 to 50 watts, according to subject capabilities), then stepwise increase in the workload, by increments of 20-40 watts every minute, until maximum tolerated workload (VO2max). Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest -10 minutes, 0, then 30 sec post beginning of exercise, 1 minute, 1 ½ minute 2, 2 ½, 3 minutes, then 3 ½ minutes, then at mid-point of every step increase in workload, until maximum tolerated workload. Recovery will be followed with the PtCO2, for 5 minutes